The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis
Eszter Káposztás, Lili Balogh, Attila Mócsai, Éva Kemecsei, Zoltán Jakus, Tamás Németh · 2023
Read The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis by Eszter Káposztás, Lili Balogh, Attila Mócsai, Éva Kemecsei, Zoltán Jakus, Tamás Németh (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10725968.txt.
Description
Eszter Káposztás and co-authors test a targeted drug in mice with a form of autoimmune arthritis. The drug, entospletinib, blocks an enzyme called Syk. That enzyme helps pass signals in immune cells. Past gene work showed that removing Syk from blood cells fully shielded mice from this arthritis. Their 2023 study asks whether the drug can match that shield.
Higher doses of the drug cut the visible signs of joint swelling in a clear dose pattern. The mice stayed in good general health. Swollen joints held fewer neutrophils and lower levels of alarm signals. Other cell counts barely moved. Lab tests showed the drug also calmed neutrophils set off by immune clumps. The team sees Syk blocking as a live option for new arthritis care.
Catalog record
| CREATOR | Eszter Káposztás, Lili Balogh, Attila Mócsai, Éva Kemecsei, Zoltán Jakus, Tamás Németh |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |